Nuo Therapeutics, Inc. (AURX) Net margin 2017–2025
Nuo Therapeutics, Inc. (AURX) net profit margin by fiscal year — reported net income divided by reported revenue.
-75.8%FY2025 · since FY2017: -2077.4% → -75.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -75.8% | +94.4 pp |
| FY2024 | -170.2% | +351.0 pp |
| FY2023 | -521.2% | +2304.4 pp |
| FY2022 | -2825.6% | — |
| FY2019 | -817.4% | -704.9 pp |
| FY2018 | -112.5% | +1964.9 pp |
| FY2017 | -2077.4% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More AURX financial trends
AURX RevenueAURX Net incomeAURX Gross profitAURX Gross marginAURX Operating incomeAURX Operating marginAURX Operating cash flowAURX Free cash flowAURX Capital expendituresAURX Return on equityAURX Stock buybacksAURX Dividends paidAURX Total assetsAURX Total liabilitiesAURX Shareholders’ equityAURX overview →